GlassScriptPhysician profile
Andrey Popykin
NPI 1952373615
$630.59
in general payments reported to CMS, 2019-2025
14 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $35.80 · 2021: $18.83 · 2022: $19.70 · 2023: $143 · 2024: $17.84 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $149.44 | 2019-2025 | Repatha, Repatha, Evenity |
| Novo Nordisk INC | $97.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $85.36 | 2019 | |
| Pfizer INC. | $76.71 | 2020-2025 | |
| Lilly USA, LLC | $61.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $19.56 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $19.48 | 2023 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $19.19 | 2025 | Gemtesa |
| Abbvie INC. | $18.83 | 2021 | |
| Dexcom, INC. | $18.68 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $18.56 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $18.23 | 2019 | |
| Merck Sharp & Dohme LLC | $14.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrey Popykin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.